A brief description of the manufacturers and instructions for use of Apelix

Apelix, this innovative drug carefully developed and produced by the world-renowned pharmaceutical company Novartis (Novartis), has made a major breakthrough in the field of breast cancer treatment. It brings new treatment hope to patients with advanced or metastatic breast cancer who carry PIK3CA mutations that are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). So, how to use this drug correctly?

According to the official drug instructions, the recommended dose of Apelvis is 300mg once a day each time. It is recommended to take it with food until the disease progresses or unacceptable toxic reactions occur. To ensure consistent efficacy, patients are advised to take the tablets at the same time every day and to swallow the tablets whole and avoid crushing, chewing or breaking them. If the patient vomits shortly after taking the medication, there is no need to take another dose, just wait for the next dose.

During the use of Apelvis, patients need to pay special attention to some possible adverse reactions. These reactions include, but are not limited to, severe hypersensitivity reactions, skin problems, high blood sugar, pneumonia, and severe diarrhea. Once these symptoms occur, patients should communicate with their doctor immediately, and the doctor may adjust the dose or discontinue the drug based on the patient's specific situation to ensure the patient's safety.

In addition, Apelvis is embryo-fetotoxic and may cause harm to the fetus. Therefore, before starting treatment, patients need to have a negative pregnancy test to rule out the possibility of pregnancy. For patients of reproductive potential, effective contraception is recommended. Patients should inform their doctor immediately if they suspect they may be pregnant.

Overall, Apelvis is an important achievement of Novartis in the field of breast cancer treatment, providing new treatment options for patients with specific types of breast cancer. However, in order to ensure the effectiveness and safety of the drug, patients must strictly follow the doctor's instructions when using Apelvis and pay close attention to any possible adverse reactions. At present, the drug is mainly sold in overseas markets, and the Indian version of the original drug is priced at about 5,000 yuan per box. Patients must choose formal channels when purchasing to ensure the quality and safety of drugs.